Unleash the Power of Data-driven Innovation

Target ID & Validation

Evotec's integrated target identification and validation approach harnesses the vast potential of large datasets, in silico tools, and therapeutic expertise to generate groundbreaking hypotheses that fuel our drug discovery pipeline. Our 3R framework -right model, right tool, right readout - delivers high-quality experimental data at every stage. 

With a focus on primary and iPSC-derived cells, coupled with deep disease understanding, we employ cutting-edge genetic and chemogenomic tools for precise target manipulation and engineering. We capture the outcomes with information-rich readouts and leverage state-of-the-art bioinformatic analysis. Built to scale, our approaches handle even larger target lists, drawing on extensive experience in phenotypic and genetic screening. Experience integrated target validation that drives confident decision-making and establishes real disease associations.

Our Capabilities

Our capabilities to identify and validate targets comprises:

  • World class platforms for generation and handling of multi-omics datasets of human disease relevant samples.
  • Dedicated in silico tools to allow for AI/ML supported data mining and hypothesis building from proprietary and public datasets.
  • Phenotypic and genetic screening using complex cellular models to mimic disease.
  • Target deconvolution expertise using methods such as chemical biology (proteomics-based), transcriptomics, cell painting and CRISPR screening.
  • Integrated 3R target validation framework that drives confident decision-making and establishes real disease associations.

Contact Our Experts

Hauke Cornils

Hauke Cornils, PhD

VP Early Discovery Actions

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.